Disclosure of transactions in own shares between 18/06/2019 and 21/06/2019

Corporate 20 June 2025 9 mins read

Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors

Corporate 31 May 2025 7 mins read

Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma

Corporate 07 May 2025 7 mins read

Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary...

Corporate 06 May 2025 5 mins read

Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation

Corporate 24 April 2025 7 mins read

Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication

Corporate 16 April 2025 6 mins read

Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance

Corporate 08 April 2025 4 mins read

Ipsen publishes its 2024 Universal Registration Document

Corporate 19 March 2025 7 mins read

Ipsen announces issuance of €500 million inaugural Rated Public Bond

Corporate 12 March 2025 5 mins read

Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins

Corporate 13 February 2025 6 mins read

Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025